Connect your AI

AngioDynamics ANGO Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

TFX

TeleflexTFX

$25.01M+129%

Merit Medical SystemsMMSI

——

HaemoneticsHAE

——

Other financials

Income statement

Revenue$78.4M+8.9%

Gross profit$41.5M+6.7%

Operating income-$13.0M-29.8%

Net income-$8.1M-83.4%

EPS (diluted)-$0.19-72.7%

Balance sheet

Cash & equivalents$37.8M-15.5%

Total debt$7.9M+10.2%

Total equity$173.4M-6.7%

Total assets$260.7M-8.7%

Cash flow

Operating cash flow-$3.1M+76.4%

CapEx$1.0M-43.5%

Free cash flow-$4.1M+72.4%

Valuation

Market cap$564.42M+38.7%

Enterprise value$534.51M+48.0%

P/S1.8×+0.4×

Profitability

Gross margin54.3%-0.1pp

Operating margin-11.3%-2.9pp

Net margin-10%-2.4pp

FCF margin5.5%—

Returns & leverage

Return on equity-17.5%-2.2pp

Debt / equity0×0.0×

Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AngioDynamics's increase (decrease) in accounts receivable?: AngioDynamics (ANGO) reported increase (decrease) in accounts receivable of $1.42M in Q4 2025.
How has AngioDynamics's increase (decrease) in accounts receivable changed year-over-year?: AngioDynamics's increase (decrease) in accounts receivable increased by 199.2% year-over-year, from $474K to $1.42M.